Exploring a new target for antibiotics against drug-resistant Acinetobacter baumannii
Official title: Determining the value of PBP 7/8 as an antimicrobial target for XDR-A. baumannnii
Funded at VA Western New York Healthcare System · NIH-10946713 · Data updated 2026-11-12
This study is looking at a special protein called PBP 7/8 to see if it can help create new antibiotics to fight Acinetobacter baumannii, a tough germ that can cause serious infections in people with weak immune systems.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Western New York Healthcare System NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | October 1, 2019 |
| Project end | September 30, 2027 |
| Funding year | 2025 |
| NIH project number | 5I01BX004677-06 |
| Project ID | NIH-10946713 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients suffering from infections caused by Acinetobacter baumannii, particularly those with antibiotic-resistant strains.
✕Less likely to help
Patients with infections caused by other types of bacteria that are not Acinetobacter baumannii may not benefit from this research.
What this research studies
This research investigates the potential of a specific protein, PBP 7/8, as a target for developing new antibiotics against Acinetobacter baumannii, a bacterium known for causing severe infections, especially in patients with weakened immune systems. The study focuses on understanding how this protein is essential for the survival of the bacteria in various environments, including in the human body. By using advanced laboratory techniques and models, the research aims to identify new antimicrobial agents that can effectively combat infections caused by highly resistant strains of this pathogen.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antibiotics that effectively treat infections caused by drug-resistant Acinetobacter baumannii.
How similar studies have gone: Other research has shown promise in targeting similar proteins in bacteria, indicating that this approach could be a viable strategy for developing new treatments.
Where this research is happening
-
VA Western New York Healthcare System
Buffalo, United States Active
Researchers
- Principal investigator: Russo, Thomas a — VA Western New York Healthcare System
- Study coordinator: Russo, Thomas a
Related research
Other NIH-funded projects on the same topics.
-
Problem-Solving Training for Concussion for Veterans with mTBI and Mental Health Symptoms
A brief, skills-focused program to help veterans with mild traumatic brain injury and co-occurring mental health symptoms recover better in everyday life.
-
Preventing and Reversing Interstitial Fibrosis in HFpEF
Aimed at aging veterans, this effort seeks to understand and tackle the heart condition HFpEF by studying how fibrosis and inflammation contribute to heart failure with preserved ejection fraction.
-
Brief problem-solving therapy to help veterans recover after concussion
A short, easy-to-access problem-solving program to help veterans with concussion plus mental health symptoms improve thinking, mood, and daily functioning.
-
Ribozyme treatment to reduce toxic retinal pigments in dry macular degeneration
This project will develop a ribozyme treatment to break down toxic pigments in the retina and help protect vision for people with dry age-related and juvenile macular degeneration.
-
Exosome therapy to protect the heart after a heart attack
Engineered cell-derived exosomes are being developed to carry protective molecules to heart cells after a heart attack to limit damage and improve recovery.
-
Protecting vision after eye or brain injuries and in a hereditary retinal condition
Working to find drug treatments that protect or slow vision loss after traumatic eye or brain injuries and in a genetic form of retinitis pigmentosa (RP59).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.